Prosecution Insights
Prosecution Insights
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (67%) |
| §112 only | 1 (17%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEHLKE, CAROLYN A | 1 | 62.0% | +29.0% |
| ORWIG, KEVIN S | 1 | 25.3% | +39.6% |
| MUSTANSIR, ABID A | 1 | 77.9% | +12.0% |
| MATALKAH, FATIMAH KHALAF | 1 | 56.3% | +11.5% |
| BERTOGLIO, VALARIE E | 1 | 64.2% | +29.6% |
| CHONG, KIMBERLY | 1 | 72.4% | +12.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282152 | REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V | ORWIG, KEVIN S | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282152 | REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V | ORWIG, KEVIN S | 2d overdue |
| 17833506 | METHOD FOR CULTURING MYOGENIC CELLS, CULTURES OBTAINED THEREFROM, SCREENING METHODS, AND CELL CULTURE MEDIUM | BERTOGLIO, VALARIE E | 5d |
| 18681739 | FIBER OPTIC NEEDLE PROBE | PEHLKE, CAROLYN A | 27d |
| 17306860 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE | CHONG, KIMBERLY | 28d |
| 17907171 | REPORTER SYSTEM FOR RADIONUCLIDE IMAGING | MATALKAH, FATIMAH KHALAF | 30d |
| 18005485 | DEVICE FOR OBTAINING AN INDICATOR OF A MICROCIRCULATORY CONDITION | MUSTANSIR, ABID A | 34d |
| Art Unit | Apps |
|---|---|
| 3799 | 1 |
| 3991 | 1 |
| 3791 | 1 |
| 1638 | 1 |
| 1632 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681739 | FIBER OPTIC NEEDLE PROBE | PEHLKE, CAROLYN A | 3799 | §103 | Final Rejection | 27d | Pending | Feb 06, 2024 |
| 18282152 | REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V | ORWIG, KEVIN S | 3991 | Other | Non-Final OA | 2d overdue | Pending | Sep 14, 2023 |
| 18005485 | DEVICE FOR OBTAINING AN INDICATOR OF A MICROCIRCULATORY CONDITION | MUSTANSIR, ABID A | 3791 | §103 | Final Rejection | 34d | Pending | Jan 13, 2023 |
| 17907171 | REPORTER SYSTEM FOR RADIONUCLIDE IMAGING | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Final Rejection | 30d | Pending | Sep 23, 2022 |
| 17833506 | METHOD FOR CULTURING MYOGENIC CELLS, CULTURES OBTAINED THEREFROM, SCREENING METHODS, AND CELL CULTURE MEDIUM | BERTOGLIO, VALARIE E | 1632 | §103 | Non-Final OA | 5d | Pending | Jun 06, 2022 |
| 17306860 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE | CHONG, KIMBERLY | 1636 | §112 | Non-Final OA | 28d | Pending | May 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial